Reshma Kewalramani
2020
In 2020, Reshma Kewalramani earned a total compensation of $9.1M as CEO and President at Vertex Pharmaceuticals, a 34% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $2,723,292 |
|---|---|
| Salary | $1,097,308 |
| Stock Awards | $5,250,411 |
| Other | $40,348 |
| Total | $9,111,359 |
Kewalramani received $5.3M in stock awards, accounting for 58% of the total pay in 2020.
Kewalramani also received $2.7M in non-equity incentive plan, $1.1M in salary and $40.3K in other compensation.
Rankings
In 2020, Reshma Kewalramani's compensation ranked 967th out of 13,090 executives tracked by ExecPay. In other words, Kewalramani earned more than 92.6% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 967 out of 13,090 | 93rd |
Division Manufacturing | 340 out of 5,617 | 94th |
Major group Chemicals And Allied Products | 115 out of 2,248 | 95th |
Industry group Drugs | 101 out of 1,948 | 95th |
Industry Pharmaceutical Preparations | 76 out of 1,453 | 95th |
Source: SEC filing on April 7, 2022.
Kewalramani's colleagues
We found three more compensation records of executives who worked with Reshma Kewalramani at Vertex Pharmaceuticals in 2020.